U2Bio Co., Ltd.
U2Bio Co., Ltd. provides healthcare services in South Korea. The company also offers specimen testing services; digital healthcare services related to testing and health examinations; and bio-technology platforms. The company was founded in 2009 and is headquartered in Seoul, South Korea.
U2Bio Co., Ltd. - Asset Resilience Ratio
U2Bio Co., Ltd. (221800) has an Asset Resilience Ratio of 68.57% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how U2Bio Co., Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down U2Bio Co., Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩30.40 Billion | 68.57% |
| Total Liquid Assets | ₩30.40 Billion | 68.57% |
Asset Resilience Insights
- Very High Liquidity: U2Bio Co., Ltd. maintains exceptional liquid asset reserves at 68.57% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
U2Bio Co., Ltd. Industry Peers by Asset Resilience Ratio
Compare U2Bio Co., Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
|
Bionet
TWO:1784 |
Diagnostics & Research | 38.62% |
|
Cytogen Inc
KQ:217330 |
Diagnostics & Research | 39.93% |
Annual Asset Resilience Ratio for U2Bio Co., Ltd. (2022–2024)
The table below shows the annual Asset Resilience Ratio data for U2Bio Co., Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 38.91% | ₩17.50 Billion | ₩44.98 Billion | +35.86pp |
| 2023-12-31 | 3.05% | ₩1.50 Billion | ₩49.20 Billion | -69.30pp |
| 2022-12-31 | 72.35% | ₩36.92 Billion | ₩51.03 Billion | -- |